Antisense DNA (IONIS-TMPRSS6-LRx) or liposomal siRNA (ALN-TMP) as well as some protease inhibitors have demonstrated specific MT-2 inhibiting activity with the potential to reduce secondary anemia in patients with iron overload in preclinical models (173–176). Here, TMPRSS6 is linked to Tangier disease.